Search Form
First, enter a politician or zip code
Now, choose a category

Key Votes

HCR 2005 - Authorizes a Manufacturer to Provide Investigational Treatments to Eligible Patients - Key Vote

Arizona Key Votes

Macario Saldate IV voted Nay (Passage) on this Legislation.

Read statements Macario Saldate IV made in this general time period.

Stages

Family

Issues

Stage Details

Legislation - Bill Passed (Senate) (23-6) - (Key vote)

Title: Authorizes a Manufacturer to Provide Investigational Treatments to Eligible Patients

Vote Smart's Synopsis:

Vote to pass a resolution that submits to the voter a question that authorizes a manufacturer to provide an investigational drug, biological product, or device to eligible patients.

Highlights:
  • Defines “investigational drug, biological product, or device” as a treatment that has successfully completed phase 1 of a clinical trial, but has not been approved for general use by the Food and Drug Administration (Sec. 1).
  • Defines “eligible patient” as an individual who meets certain criteria, including, but not limited to, the following (Sec. 1):
    • The individual has a terminal illness as determined by their physician and a consulting physician;
    • The individual’s physician has determined that there is no satisfactory or comparable Food and Drug Administration approved treatment; and
    • The individual has received a recommendation from their physician for the investigational treatment.
  • Authorizes a manufacturer to require an individual to pay for investigational treatment and to participate in data collection relating to the treatment (Sec. 1).
  • Specifies that a health care insurer or any state agency does not have to provide coverage for the cost of the investigational treatment (Sec. 1).
  • Prohibits any state regulatory board from revoking or failing to renew a physician’s license based on the physician’s recommendation of an investigational treatment (Sec. 1).
  • Specifies that any official, employee, or agent of the state who blocks an eligible patient’s access to an investigational treatment is guilty of a class 1 misdemeanor (Sec. 1).
Legislation - Bill Passed (House) (31-23) - (Key vote)

Title: Authorizes a Manufacturer to Provide Investigational Treatments to Eligible Patients

Vote Smart's Synopsis:

Vote to pass a resolution that submits to the voter a question that authorizes a manufacturer to provide an investigational drug, biological product, or device to eligible patients.

Highlights:
  • Defines “investigational drug, biological product, or device” as a treatment that has successfully completed phase 1 of a clinical trial, but has not been approved for general use by the Food and Drug Administration (Sec. 1).
  • Defines “eligible patient” as an individual who meets certain criteria, including, but not limited to, the following (Sec. 1):
    • The individual has a terminal illness as determined by their physician and a consulting physician;
    • The individual’s physician has determined that there is no satisfactory or comparable Food and Drug Administration approved treatment; and
    • The individual has received a recommendation from their physician for the investigational treatment.
  • Authorizes a manufacturer to require an individual to pay for investigational treatment and to participate in data collection relating to the treatment (Sec. 1).
  • Specifies that a health care insurer or any state agency does not have to provide coverage for the cost of the investigational treatment (Sec. 1).
  • Prohibits any state regulatory board from revoking or failing to renew a physician’s license based on the physician’s recommendation of an investigational treatment (Sec. 1).
  • Specifies that any official, employee, or agent of the state who blocks an eligible patient’s access to an investigational treatment is guilty of a class 1 misdemeanor (Sec. 1).
Legislation - Introduced (House) -

Title: Authorizes a Manufacturer to Provide Investigational Treatments to Eligible Patients

Sponsors

Co-sponsors

Skip to top
Back to top